Growth | Trends and Analysis For Blood Culture Tests Market
The blood culture tests market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of of the global blood culture tests market in 2019. However, the Asia Pacific market is expected to register the highest CAGR during the forecast period.
Growth in the blood culture tests market is attributed to factors such as increasing number of sepsis cases and high cost of treatment, rising geriatric population, high incidence of bloodstream infections, growth in the demand for rapid diagnostic techniques, and the high prevalence of infectious diseases.
The COVID-19 pandemic has affected manufacturing and construction activities worldwide. Logistic limitations and reconsiderations of the raw material requirements are becoming a problem for manufacturers.
Numerous manufacturers found themselves in situations where demand greatly exceeded supply, and therefore, many laboratories struggled to continue to offer testing in some areas. This negatively affected the blood culture tests market.
The COVID-19 pandemic that began in Wuhan, China, has caused significant disruptions to businesses and economic activities worldwide. COVID-19 is expected to have a negative impact on the blood culture tests market due to the limited or non-availability of medical facilities/treatment centers. To reduce the strain on the healthcare system and decrease disease transmission, governments worldwide are providing guidelines to postpone or delay non-essential medical and surgical procedures. Restrictions and lockdowns were also imposed in the areas of travel, business operations, public gatherings, health clubs, and fitness/wellness centers.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=159606753
Nosocomial (hospital-acquired) bloodstream infections are one of the leading causes of mortality across the globe. In the US alone, approximately 250,000 cases of hospital-acquired BSIs occur each year. Globally, bloodstream infections affect about 30 million people leading to 6 million deaths, with 3 million newborns and 1.2 million children suffering from sepsis annually.
In Eastern African countries, the proportion of patients with bloodstream infections is reported to range from 11% to 28%. In Ghana, bloodstream infection rates are estimated to be in the range of 9.3% to 11.2% (Source: Journal of Tropical Medicine, 2019). The occurrence of these infections increases the overall duration of hospitalization as well as the cost of treatment. With the high incidence of BSIs, the demand for advanced blood culture techniques that help in the early detection of infections is expected to increase.
The high growth in these markets can primarily be attributed to the growth in the prevalence of infectious diseases, rapid growth in the geriatric population, the growing number of product approvals, and rising healthcare expenditure. For instance, the healthcare expenditure in China increased to 5.35% of the GDP in 2018 from USD 4.88% of GDP in 2015 (Source: World Bank, OECD).
Such significant spending will result in the adoption of advanced systems, such as automated blood culture systems, among hospital and reference laboratories in these regions. This, in turn, is expected to provide potential growth opportunities for players operating in the blood culture tests market in the coming years.
On the basis of product, the blood culture tests market is segmented into consumables, instruments, and software and services. Consumables is the largest and fastest-growing segment, in 2019. This segment is also projected to register the highest CAGR from 2020 to 2025. The recurring requirement of consumables as compared to instruments is the key factor driving the growth of this segment..
The major players in the blood culture tests market are Becton, Dickinson and Company (US), bioMérieux SA (France), and Thermo Fisher Scientific Inc. (US). These companies together accounted for a share of more than 60% of the blood culture tests market in 2019. Other players in the market include Luminex Corporation (US), Danaher Corporation (US), Bruker Corporation (US), IRIDICA (a subsidiary of Abbott Laboratories) (US), Roche Diagnostics (Switzerland), T2 Biosystems, Inc. (US), Anaerobe Systems, Inc. (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan), BINDER GmbH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio, Inc. (US), Axiom Laboratories (India), and HiMedia Laboratories Pvt. Ltd. (India) among others.